Celldex posts investor presentation highlighting barzolvolimab late-stage chronic urticaria program milestones

Reuters2026/08/14 21:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Celldex outlined a late-stage immunology pipeline centered on barzolvolimab, a KIT antagonist antibody targeting mast cells.
Phase 3 CSU program enrollment completed 6 months ahead of guidance; topline data expected in Sept/Oct 2026.
Topline readout set to cover both EMBARQ-CSU trials, Week 12 primary endpoint, safety through Week 24.
Phase 3 ColdU/SD study initiated in Dec 2025; Phase 2 atopic dermatitis study fully enrolled with topline data expected late 2026.
CDX-622 bispecific targeting TSLP and SCF posted positive Phase 1 healthy-volunteer data; Phase 1 asthma proof-of-mechanism study started Jan 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celldex posts investor presentation highlighting barzolvolimab late-stage chronic urticaria program milestones

You may also like

Crypto prices